Lilly lawsuit could preserve $3.3bn of Sanofi revenues
This article was originally published in Scrip
Executive Summary
The mere act of filing a lawsuit against Lilly appears to have boosted Sanofi's top-line prospects to the tune of several billion dollars. The firm, which has made a tactical play that should hold a biosimilar version of its top-selling product off the US market for an extra 16 months even if it eventually loses the patent battle, could make an extra $3.3bn in sales for the four years from 2015 to 2018, according to the revised forecast from Goldman Sachs.